- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Mirza on Hematuria and a Bladder Cancer Diagnosis
May 17th 2014, 9:24am
Moben Mirza, MD, assistant professor of urology at the University of Kansas Medical Center, discusses a study presented at the 2014 AUA Annual Meeting that evaluated gender and race variation in the workup of hematuria.
Dr. Rhee Discusses Workplace Violence in Urology Practices
May 17th 2014, 7:48am
Eugene Y. Rhee, MD, chief of urology, Kaiser Permanente, discusses workplace violence in urology practices.
As Lung Cancer Screening Debate Continues, Study Projects Implementation Outcomes
May 14th 2014, 1:10pm
In December 2013, the US Preventive Services Task Force (USPSTF) recommended that asymptomatic, high-risk individuals receive annual screening for lung cancer with low-dose computed tomography (LDCT).
Novel TKI May Provide New Treatment Option for Patients With Recurrent PVNS
May 14th 2014, 1:05pm
The new targeted drug, PLX3397, has demonstrated responses in patients with pigmented villonodular synovitis (PVNS), a rare joint disorder.
For Premenopausal Women With ER-Positive Disease, Obesity Is a Major Risk Factor in Breast Cancer Mortality
May 14th 2014, 1:00pm
Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.
Delaying ADT Until Symptoms Appear Does Not Impact Survival, Study Suggests
May 14th 2014, 1:00pm
A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.
AZD9291 Shows Robust Activity in Resistant EGFR-positive NSCLC
May 14th 2014, 1:00pm
The highly selective EGFR inhibitor AZD9291 demonstrated an overall response rate of 64% without inducing dose-limiting toxicities in patients with metastatic NSCLC who harbor an acquired EGFR T790M resistance mutation.
Irregular Menstruation Linked to Higher Risk of Ovarian Cancer Death
April 9th 2014, 8:44am
A prospective study found that women with irregular menstrual cycles have a 2.4-fold increased risk of dying from ovarian cancer compared to women with normal menstrual cycles
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
April 7th 2014, 12:07pm
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
Dr. Flynn on CDK Inhibitors for the Treatment of CLL
April 7th 2014, 12:02pm
Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).
David Lucas Discusses the Bromodomain Inhibitor OTX015
April 7th 2014, 11:31am
David Lucas, PhD, assistant professor, division of hematology, Ohio State University, discusses the bromodomain inhibitor OTX015.
I-SPY 2 Trial Graduates Neratinib for HER2-Positive Breast Cancer
April 7th 2014, 6:42am
The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer
Palbociclib Dramatically Improves PFS in Updated Phase II Findings
April 7th 2014, 6:40am
The combination of palbociclib and letrozole more than doubled PFS and showed a non–statistically significant 4.2-month improvement in OS for patients with ER-positive, HER2-negative metastatic breast cancer.
CDK4/6 Inhibitor LY2835219 Shows Promise in Early Study
April 7th 2014, 6:00am
The CDK4/6 inhibitor LY2835219 demonstrated promising single-agent activity in heavily pretreated patients with HR-positive metastatic breast cancer.
Immunotherapies Promising But Still Challenging in CRPC
March 17th 2014, 11:53am
Interdisciplinary Prostate Cancer Congress
Increasing efficacy with immunotherapies in some cancers led to the strategy being deemed Breakthrough of the Year by Science magazine in 2013
Dr. Crawford on Rebiopsying for Prostate Cancer
March 17th 2014, 7:42am
Interdisciplinary Prostate Cancer Congress
E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.
Continue Screening for PSA But Treat Judiciously
March 17th 2014, 7:20am
Interdisciplinary Prostate Cancer Congress
Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, so America's medical community should continue to offer the test to appropriate men, but at the same time should work harder to avoid the screen's potential pitfalls.
Growing Role for Androgen-Targeting Therapies in CRPC
March 17th 2014, 6:59am
Interdisciplinary Prostate Cancer Congress
A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the management of CRPC.
Dr. Sartor Discusses PSA Testing for Prostate Cancer
March 17th 2014, 6:38am
Interdisciplinary Prostate Cancer Congress
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the controversies surrounding PSA screening for prostate cancer.
7th Annual IPCC to Advance Multidisciplinary Care for Prostate Cancer
March 14th 2014, 7:19am
Interdisciplinary Prostate Cancer Congress
Insights about PSA screening, genomics, and what's new in the areas of imaging, antiandrogen therapy, radiation therapy, immunotherapy, and radiopharmaceuticals will be offered during the 7th Annual IPCC.